Advertisement
Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robinson, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robinson, R. F.
American Journal of Health-System Pharmacy, Vol. 65, Issue 23_Supplement_8, S3-S6
Copyright © 2008. American Society of Health-System Pharmacists, Inc. All rights reserved. 1079-2082/04/0602-1242$06.00

Impact of respiratory syncytial virus in the United States

Renee F. Robinson

RENEE F. ROBINSON, PHARM.D., MPH, is Clinical Pharmacy Manager, Critical Care Systems, Inc., 705 F Lakeview Plaza Blvd., Worthington, OH 43085 (rrobinson{at}criticalcaresystems.com).


Purpose. Respiratory syncytial virus (RSV) infection is most common in infants and young children, with almost all children experiencing at least one infection by their second birthday.

Summary. RSV is the leading cause of upper and lower respiratory tract infections in infants and young children, and is the most common cause of bronchiolitis and pneumonia in children younger than one year of age. Since infection with RSV does not result in permanent immunity, repeat infections are common, often occurring during the same RSV season. RSV bronchiolitis is the leading cause of hospitalization in children younger than age one, and this virus is associated with approximately 75,000 to 125,000 hospitalizations annually in the United States. Children hospitalized for RSV bronchiolitis during the first year of life are at an increased risk of respiratory problems, such as wheezing and allergic asthma, throughout childhood and into adolescence. RSV-related mortality has decreased over the last 20 years; however, RSV is still the leading cause of viral deaths in infants.

Conclusion. RSV infection is associated with significant disease burden in infants and young children in terms of hospitalization, related complications, and even mortality. The economic burden resulting from RSV disease is also substantial, with significantly higher costs seen in children with risk factors for severe disease and RSV-related complications.

Index terms: Economics; Epidemiology; Mortality; Pediatrics; Respiratory syncytial virus infections; United States

 






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society of Health-System Pharmacists.
Advertisement